Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group is in the news again with the CO.17 trial

The results of the first set of correlative biomarker analyses (on K-ras) were published in the current New England Journal of Medicine as the lead article. The results of the trial suggest that investigators are now able to identify those patients with advanced colorectal cancer who are most likely to benefit from cetuximab. Treatment with cetuximab (a monoclonal antibody directed against the epidermal growth factor receptor -- EGFR) improves overall and progression-free survival and preserves the quality of life in patients with colorectal cancer that has not responded to chemotherapy.

This could mean that, in the future, patients can be identified prior to treatment to determine if they are likely to respond. And, just as importantly, it means investigators can identify those patients who are not likely to benefit sparing them unnecessary treatment, and the related side effects. Being able to identify and treat only those patients who will be benefit from cetuximab could also help save on healthcare costs.

To read more about these exciting results, see the following links:
New England Journal of Medicine:
New England Journal of Medicine leading editorial:
Canadian Cancer Society:

Thank you to all who contributed to the success of this study!